Next Article in Journal
Entering an Unseen World and the Discoveries of George Palade
Previous Article in Journal
Consensus Statement on the Management of Patients with HCV Infection in Romania
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
GERMS
Volume 7
Issue 1
10.18683/germs.2017.1107
germs-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Opinion

Resistance Testing for the Treatment of Chronic Hepatitis C with Direct Acting Antivirals: When and for How Long?

by
Ana Belén Pérez
,
Natalia Chueca
and
Federico García
*
Clinical Microbiology Department, Infectious Diseases & Clinical Microbiology Unit, Hospital Universitario San Cecilio, Instituto de Investigación Ibs.Granada, Av. de la Innovación S/N, 18016 Granada, Spain
*
Author to whom correspondence should be addressed.
GERMS 2017, 7(1), 40-44; https://doi.org/10.18683/germs.2017.1107
Submission received: 16 February 2017 / Revised: 20 February 2017 / Accepted: 25 February 2017 / Published: 1 March 2017
Versions Notes

Abstract

The need to test for resistance associated substitutions (RAS) has been intensively debated in the past two years. In the absence of pangenotypic combinations, it seems reasonable that, if available, RAS testing in the NS5A gene at baseline for genotypes 1a and 3 may help to avoid overtreatment in terms of ribavirin usage and/or prolonged treatment duration. When patients fail treatment, RAS testing may also be useful to guide the selection of the new regimen, especially for those that need urgent retreatment and that have failed a combination including an NS5A inhibitor. However, there are new drugs in the pipeline that in combination are pangenotypic, very potent and with a high genetic barrier to resistance. In this new scenario, RAS testing may not play such an important role.
Keywords: HCV; RAS; DAA; baseline; failure; new drugs HCV; RAS; DAA; baseline; failure; new drugs

Share and Cite

MDPI and ACS Style

Pérez, A.B.; Chueca, N.; García, F. Resistance Testing for the Treatment of Chronic Hepatitis C with Direct Acting Antivirals: When and for How Long? GERMS 2017, 7, 40-44. https://doi.org/10.18683/germs.2017.1107

AMA Style

Pérez AB, Chueca N, García F. Resistance Testing for the Treatment of Chronic Hepatitis C with Direct Acting Antivirals: When and for How Long? GERMS. 2017; 7(1):40-44. https://doi.org/10.18683/germs.2017.1107

Chicago/Turabian Style

Pérez, Ana Belén, Natalia Chueca, and Federico García. 2017. "Resistance Testing for the Treatment of Chronic Hepatitis C with Direct Acting Antivirals: When and for How Long?" GERMS 7, no. 1: 40-44. https://doi.org/10.18683/germs.2017.1107

APA Style

Pérez, A. B., Chueca, N., & García, F. (2017). Resistance Testing for the Treatment of Chronic Hepatitis C with Direct Acting Antivirals: When and for How Long? GERMS, 7(1), 40-44. https://doi.org/10.18683/germs.2017.1107

Article Metrics

Back to TopTop